Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) both fill the kidneys with fluid-filled cysts, but they differ sharply in their genetic causes, typical age of onset, organ involvement, and available treatments. ADPKD is one of the most common inherited disorders in humans, affecting roughly one in 400 to one in 1,000 people worldwide and usually showing up in adulthood.1PubMed Central. Autosomal dominant polycystic kidney disease ARPKD is far rarer, primarily strikes infants and children, and carries a much grimmer short-term prognosis. Understanding how these two diseases diverge is useful for anyone navigating a family diagnosis, weighing genetic screening, or simply trying to make sense of a confusing naming convention.
The Genetic Split
ADPKD traces to mutations in one of two genes, PKD1 or PKD2, which produce proteins called polycystin 1 and polycystin 2. Roughly 85 percent of ADPKD cases involve PKD1, and those tend to run a more severe clinical course than PKD2 cases.1PubMed Central. Autosomal dominant polycystic kidney disease Because the disease is dominant, inheriting just one faulty copy of either gene from one parent is enough to cause disease. Each child of an affected parent has a 50 percent chance of inheriting it.
ARPKD, by contrast, results from mutations in a single gene called PKHD1, which encodes a large protein called fibrocystin. This protein appears to function as a receptor molecule that helps maintain the normal structure of kidney tubule cells.2PubMed Central. Fibrocystin/polyductin (FPC): new functional insights into ARPKD pathogenesis revealed by informatics, comparative genomics, and model systems Because the disease is recessive, a child must inherit two defective copies of PKHD1, one from each parent, to develop symptoms. Carrier parents typically have no kidney problems themselves and may have no idea they carry the mutation until a child is diagnosed.
The story gets more complicated than the clean “dominant versus recessive” framing suggests. Research has shown that PKD1 and PKD2, the genes behind ADPKD, can also occasionally be inherited in a recessive pattern, producing severe early-onset disease that looks more like ARPKD than classic ADPKD. This evidence points to a dosage-sensitive network where the total amount of functional polycystin protein, rather than a simple on-or-off gene switch, determines how severe the disease becomes.3PubMed Central. ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies
When and How Each Disease Shows Up
ARPKD almost always presents during childhood, and severe cases announce themselves before birth. Fetal kidneys that cannot produce enough urine lead to dangerously low amniotic fluid, a condition that can compromise lung development. In some pregnancies, doctors perform amniotic fluid infusions to try to give the lungs enough room to mature.4PubMed Central. Fatal outcome of autosomal recessive polycystic kidney disease in neonates with recessive PKHD1 mutations Newborns with the most severe forms face life-threatening respiratory and kidney failure in their first days. Children who survive infancy may still progress to end-stage kidney disease during childhood or adolescence.
ADPKD follows a much slower timeline. Cysts grow gradually for decades, and most people have normal or near-normal kidney function until their 30s or 40s. About half of affected individuals reach end-stage kidney disease by age 60.1PubMed Central. Autosomal dominant polycystic kidney disease Early-onset ADPKD does happen occasionally, especially in people who carry mutations in both PKD1 alleles or in combination with other cystic disease genes, which can mimic the severity of ARPKD in young children.3PubMed Central. ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies
What Cilia Have to Do with It
Both diseases are classified as ciliopathies, meaning they involve defects in primary cilia, the tiny antenna-like structures that project from the surface of kidney cells. Primary cilia act as sensors, picking up signals from the surrounding fluid environment and relaying them into the cell.5PubMed Central. Cilia and polycystic kidney disease, kith and kin When the proteins encoded by PKD1, PKD2, or PKHD1 malfunction, this signaling goes haywire. Cells lose their normal growth restraints, start proliferating, and secrete fluid into sealed-off pockets that balloon into cysts.6PubMed. Ciliopathies and the Kidney: A Review
In ADPKD specifically, the polycystin proteins normally sit on the cilium and suppress a cyst-promoting signal. When they are absent or broken, that signal goes unchecked.7Trends in Molecular Medicine. Polycystins and cilia in the control of kidney lumen diameter Research on ARPKD suggests that loss of fibrocystin disrupts intracellular calcium signaling, which in turn triggers abnormal cell proliferation and cyst formation.8PubMed. PKHD1 gene silencing may cause cell abnormal proliferation through modulation of intracellular calcium in autosomal recessive polycystic kidney disease In both diseases, once cysts form, they accumulate fluid. In ADPKD, cyst-lining cells actively secrete chloride through a channel called CFTR, drawing water into the cyst and inflating it further. This secretion is driven by elevated levels of a signaling molecule called cAMP.9Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease. Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease
Liver Disease and Other Organs
One of the starkest differences between ADPKD and ARPKD involves the liver. Every patient with ARPKD has congenital hepatic fibrosis, a condition where the liver’s bile duct architecture is abnormal and scar tissue accumulates. This fibrosis often leads to portal hypertension, which causes enlarged veins, an enlarged spleen, and a risk of life-threatening bleeding. In some ARPKD patients, the liver disease becomes as big a clinical problem as the kidney disease itself.10Journal of Pediatric Gastroenterology and Nutrition. Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease
ADPKD patients get a different liver problem: polycystic liver disease, where fluid-filled cysts grow in the liver just as they do in the kidneys. These liver cysts are usually asymptomatic, though in some people they grow large enough to cause abdominal discomfort or compression of nearby organs. Congenital hepatic fibrosis in ADPKD is extremely rare.10Journal of Pediatric Gastroenterology and Nutrition. Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease
Cardiovascular Risks in ADPKD
ADPKD carries cardiovascular baggage that goes well beyond the kidney. Hypertension typically develops early in the disease course, often before any detectable loss of kidney function. But even in young ADPKD patients with normal blood pressure and well-preserved kidney function, researchers have found thickened artery walls, stiff ventricles, impaired blood-vessel relaxation, and reduced coronary blood flow. These findings suggest that cardiovascular damage begins very early and is driven at least partly by the polycystin defect itself, not just by failing kidneys.11PubMed Central. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease
The most feared vascular complication is intracranial aneurysm, a weakened bulge in a brain artery that can rupture and cause a hemorrhagic stroke. A study screening 355 ADPKD patients found an overall aneurysm prevalence of about 12 percent, climbing to roughly 23 percent in people aged 60 to 69. Those with a family history of aneurysm or hemorrhagic stroke had about double the risk compared to ADPKD patients without such a family history. The authors recommended systematic screening with brain MRI for ADPKD patients, especially those over 30 or those with a positive family history.12PubMed. Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease These vascular complications are not a recognized feature of ARPKD.
How Each Disease Is Tracked
Because ADPKD progresses so slowly, doctors need a way to measure whether the disease is getting worse before kidney function numbers start dropping. Total kidney volume, measured by imaging, has become the go-to biomarker. A study analyzing over a thousand ADPKD patients found that total kidney volume measured by ultrasound, CT, or MRI was strongly associated with later decline in kidney function and progression to end-stage disease, regardless of which imaging method was used.13PubMed Central. Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease Total kidney volume has essentially become the gold standard for tracking ADPKD at early stages and for evaluating treatments in clinical trials.14Nephrology Dialysis Transplantation. Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression
Prenatal ultrasound and genetic testing play a larger role in ARPKD, where the disease often declares itself before birth with massively enlarged kidneys and reduced amniotic fluid. For ADPKD, prenatal detection is rarer but possible; ultrasound can occasionally reveal enlarged kidneys in a fetus, and genetic testing can confirm the diagnosis, which is valuable for family counseling and early management planning.15PubMed Central. Prenatal Diagnosis of Autosomal Dominant Polycystic Kidney Disease: Case Report
Treatments for ADPKD
The only drug approved specifically for ADPKD is tolvaptan, a vasopressin receptor blocker that works by reducing the cAMP-driven fluid secretion that inflates cysts. In the landmark TEMPO 3:4 trial, tolvaptan slowed kidney growth to about 2.8 percent per year compared with 5.5 percent per year in the placebo group over three years, and it slowed the rate of kidney function decline as well. Pain events related to ADPKD were also less common. The tradeoff: tolvaptan causes extreme thirst and frequent urination (the kidneys are dumping water as part of the drug’s mechanism), and it carries a risk of liver injury, which contributed to a higher dropout rate in the treatment group.16PubMed Central. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease Follow-up analysis showed that patients whose urine became the most dilute on the drug, reflecting a stronger response, experienced the greatest benefit in slowing kidney decline.17PubMed Central. Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial
Blood pressure control is another pillar of ADPKD management. The HALT-PKD trials tested whether aggressive blood pressure targets could slow cyst growth. In early-stage ADPKD patients, keeping systolic blood pressure below 110 compared with the standard target of 120 to 130 resulted in significantly slower kidney volume growth at about 5.6 percent per year versus 6.6 percent, along with improvements in heart size and protein spillage in urine.18PubMed Central. Blood pressure in early autosomal dominant polycystic kidney disease In later-stage disease, though, combining two blood pressure medications provided no additional benefit over a single agent.19PubMed Central. Angiotensin blockade in late autosomal dominant polycystic kidney disease The practical message: tight blood pressure control matters most when started early.
Treatments for ARPKD
No drug is approved specifically for ARPKD, and management is largely supportive: controlling blood pressure, managing the liver complications, and preparing for transplantation if organs fail. Because ARPKD affects both kidneys and liver, the transplant decision is more complex than in ADPKD. Some patients need only a kidney transplant, but those with severe liver fibrosis and portal hypertension may need a combined liver-kidney transplant.
Registry data from Europe on young ARPKD patients who received transplants showed that overall five-year patient survival was about 95 percent. However, survival was notably lower after combined liver-kidney transplant compared with kidney transplant alone: roughly 87 percent versus 97 percent. The risk of death was nearly sevenfold higher with the combined procedure.20PubMed. Kidney Versus Combined Kidney and Liver Transplantation in Young People With Autosomal Recessive Polycystic Kidney Disease A smaller single-center series of eight children who received combined transplants reported that all survived, with stable organ function and significant improvements in growth over three years, though liver and kidney graft survival rates were 72 and 88 percent respectively.21PubMed. Combined liver-kidney transplantation for children with autosomal recessive polycystic kidney disease (ARPKD): indication and outcome Deciding which patients need the combined operation remains challenging and controversial; clinicians look at the degree of portal hypertension, ultrasound trends, and liver biopsy findings to guide the call.22PubMed Central. New approaches to the autosomal recessive polycystic kidney disease patient with dual kidney-liver complications
Diet, Ketosis, and Experimental Approaches
Animal studies generated excitement by showing that caloric restriction and ketogenic diets could dramatically slow cyst growth in mouse models of polycystic kidney disease. The results in one widely cited study were striking enough that the authors proposed dietary intervention as a potential treatment strategy for ADPKD.23Cell Metabolism. Ketosis and Ketogenic Diet Ameliorate Polycystic Kidney Disease Progression The first randomized controlled trial in humans, however, was more sobering. People on a ketogenic diet did see a small decrease in kidney volume while the control group’s kidneys grew, but the difference did not reach statistical significance.24Cell Reports Medicine. Ketogenic dietary interventions in autosomal-dominant polycystic kidney disease (KETO-ADPKD): A randomized controlled trial Whether longer or more rigorous dietary interventions would yield significant results remains unclear.25PubMed Central. Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don’t
Metformin has also attracted research interest. In early ADPKD mouse models, metformin slowed cyst growth, potentially by tamping down CFTR-mediated fluid secretion and suppressing growth-signaling pathways.26The FASEB Journal. Metformin Inhibits Cyst Growth and Alters Cell Metabolism in Vitro and Improves Relevant Disease Parameters in a Hypomorphic ADPKD Mouse Model Human trials are ongoing, though no definitive results are available yet.
On the ARPKD side, gene therapy research is in very early stages. One approach targets the CFTR chloride channel in abnormal bile ducts, which drive cyst formation in the liver. In mouse experiments, delivering a truncated form of the CFTR gene via a viral vector reduced liver cyst size and cell proliferation, effectively rescuing the ARPKD liver phenotype.27Physiology. A novel gene therapy for Autosomal Recessive Polycystic Kidney Disease based on CFTR This is years from clinical use, but it represents one of the first gene-therapy strategies specifically designed for ARPKD.
Living with ADPKD and Pain
ADPKD is often described in clinical terms, but the lived experience involves chronic pain that rarely gets enough attention. Data from a large U.S. patient registry found that dull kidney pain was most common in people with advanced kidney disease, but sharp kidney pain was spread evenly across early disease stages, meaning you do not have to be close to kidney failure to experience significant pain.28PubMed Central. Pain and Health-Related Quality of Life in Autosomal Dominant Polycystic Kidney Disease: Results from a National Patient-Powered Registry Pain in ADPKD can come from cyst rupture, cyst infection, kidney stones (which are more common in polycystic kidneys), or simply the mechanical burden of massively enlarged organs pressing on surrounding tissues.
Quality-of-life research in ARPKD is thinner, partly because the patient population is much smaller and skews younger. For children with ARPKD, the burden falls heavily on families navigating intensive medical care, repeated hospitalizations, and decisions about transplantation. Growth delays are common, and catching up in height after transplant is one measurable quality-of-life win.
Prenatal Testing and Reproductive Decisions
Because ADPKD is dominant, affected individuals face a straightforward but emotionally fraught probability: each pregnancy carries a one-in-two chance of passing on the gene. Survey research found a notable split in how patients feel about reproductive testing. Only about 17 to 18 percent would consider prenatal diagnosis followed by possible termination, but roughly 50 to 63 percent expressed interest in preimplantation genetic testing, the kind that screens embryos before an IVF pregnancy is established.29PubMed. Attitudes in Patients with Autosomal Dominant Polycystic Kidney Disease Toward Prenatal Diagnosis and Preimplantation Genetic Diagnosis The gap suggests that many patients want the option to prevent transmission but are uncomfortable with traditional prenatal testing and its implications.
For ARPKD, reproductive counseling takes a different shape. Carrier parents have a one-in-four chance with each pregnancy. Because ARPKD carriers show no symptoms, many families learn about their carrier status only after a child is diagnosed. Genetic screening of the PKHD1 gene can identify carrier couples before a first affected pregnancy, though this level of screening is not yet routine outside of families with known disease.